Download PDF
Thromb Haemost 2024; 124(02): 108-121
DOI: 10.1055/a-2165-1000
Coagulation and Fibrinolysis

Anti-thrombotic Effects Mediated by a Novel Dual-Target Peptide Inhibiting Both Platelet Aggregation and Thrombin Activity without Causing Bleeding

Jinchao Yu
1   Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, School of Basic Medical Sciences, Fudan University, Shanghai, China
2   The Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China
,
Tianfa Wang
1   Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, School of Basic Medical Sciences, Fudan University, Shanghai, China
2   The Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China
,
Xiaohan Zhang
1   Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, School of Basic Medical Sciences, Fudan University, Shanghai, China
2   The Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China
,
Qing Chen
3   The Department of Clinical Laboratory, Shanghai Mental Health Center, Shanghai, China
,
Yajun Hu
1   Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, School of Basic Medical Sciences, Fudan University, Shanghai, China
2   The Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China
,
Qiaoyan Liang
1   Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, School of Basic Medical Sciences, Fudan University, Shanghai, China
2   The Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China
,
Yun Shi
4   Department of Immunology and Theranostics, Arthur Riggs Diabetes and Metabolism Research Institute, Beckman Research Institute of the City of Hope, Duarte, California, United States
,
Yuxiong Wang
1   Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, School of Basic Medical Sciences, Fudan University, Shanghai, China
2   The Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China
,
Yanling Zhang
1   Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, School of Basic Medical Sciences, Fudan University, Shanghai, China
2   The Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China
,
Min Yu
1   Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, School of Basic Medical Sciences, Fudan University, Shanghai, China
2   The Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China
,
Bing Zhao
1   Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, School of Basic Medical Sciences, Fudan University, Shanghai, China
2   The Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China
› Author Affiliations Funding This study was supported by the National Natural Science Foundation of China (NSFC 82273293) and Shanghai Municipal Health Commission Health Industry Clinical Research Project (20224Y0120).
› Further Information
Also available at
    Permissions and Reprints


Abstract

Background Classical anticoagulants and antiplatelets are associated with high frequencies of bleeding complications or treatment failure when used as single agents. Thrombin plays an important role in the blood coagulation system. GP IIb/IIIa is the central receptor of platelets, which can recognize the Arg-Gly-Asp (RGD) sequence and activate platelets.

Material and Methods Molecular simulation and homology modeling were performed to design a novel dual-target anticoagulant short peptide (PTIP ). The activities of PTIP on coagulation and platelet in vitro were analyzed. The antithrombotic activity of PTIP was determined by pulmonary thromboembolism model, ferric chloride injury model and arteriovenous bypass thrombosis model. Bleeding effect and toxicity of PTIP were evaluated.

Results We have constructed a novel dual-target peptide (PTIP) based on the direct thrombin inhibitor peptide (DTIP). PTIP was expressed at high levels in Pichia pastoris. PTIP interfered with thrombin-mediated coagulation and ADP-induced platelet aggregation in vitro. When injected intravenously or subcutaneously, PTIP showed potent and dose-dependent extension of aPTT and PT which were similar to DTIP; but only PTIP was capable of inhibiting platelet aggregation. PTIP (1.0 mg/kg) decelerated thrombosis formation in venous and arterial vessels induced by FeCl3 injury. PTIP (1.0 mg/kg) also prevented deep venous thrombosis and increased the survival rate associated with pulmonary thromboembolism. And PTIP effectively reduced thrombus length in arteriovenous bypass thrombosis model. Moreover, the antithrombotic dose of PTIP could not induce bleeding.

Conclusion These data establish that PTIP represents a novel antithrombotic agent whose effects involve both inhibition of platelet activation and reduction of fibrin generation. And PTIP not only can be used in venous thrombosis and arterial thrombosis, it can also replace the combined treatment of antiplatelet and anticoagulant drugs in thrombotic diseases.

Keywords

thrombin - platelet - thrombosis - dual-target peptide

Authors' Contribution

B.Z., M.Y., and J.Y. performed all of the experiments; T.W., X.Z., Q.C., Y.H., Y.S., Y.Z., and Y.W. participated in the research and collected the samples; B.Z. and J.Y. designed experiments, analyzed data, and wrote the paper. All authors read and approved the final manuscript.


Supplementary Material



Publication History

Received: 21 June 2023

Accepted: 30 August 2023

Accepted Manuscript online:
01 September 2023

Article published online:
25 September 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 GBD 2016 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390 (10100): 1260-1344
    CrossrefPubMedSearch in Google Scholar
  • 2 Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol 2007; 27 (08) 1687-1693
    CrossrefPubMedSearch in Google Scholar
  • 3 Tanaka KA, Key NS, Levy JH. Blood coagulation: hemostasis and thrombin regulation. Anesth Analg 2009; 108 (05) 1433-1446
    CrossrefPubMedSearch in Google Scholar
  • 4 Brummel KE, Paradis SG, Butenas S, Mann KG. Thrombin functions during tissue factor-induced blood coagulation. Blood 2002; 100 (01) 148-152
    CrossrefPubMedSearch in Google Scholar
  • 5 Mackman N, Bergmeier W, Stouffer GA, Weitz JI. Therapeutic strategies for thrombosis: new targets and approaches. Nat Rev Drug Discov 2020; 19 (05) 333-352
    CrossrefPubMedSearch in Google Scholar
  • 6 Lee CJ, Ansell JE. Direct thrombin inhibitors. Br J Clin Pharmacol 2011; 72 (04) 581-592
    CrossrefPubMedSearch in Google Scholar
  • 7 Sharma S, Tyagi T, Antoniak S. Platelet in thrombo-inflammation: unraveling new therapeutic targets. Front Immunol 2022; 13: 1039843
    CrossrefPubMedSearch in Google Scholar
  • 8 Mackman N. Triggers, targets and treatments for thrombosis. Nature 2008; 451 (7181): 914-918
    CrossrefPubMedSearch in Google Scholar
  • 9 Blue R, Kowalska MA, Hirsch J. et al. Structural and therapeutic insights from the species specificity and in vivo antithrombotic activity of a novel alphaIIb-specific alphaIIbbeta3 antagonist. Blood 2009; 114 (01) 195-201
    CrossrefPubMedSearch in Google Scholar
  • 10 Kuo YJ, Chang YT, Chung CH, Chuang WJ, Huang TF. Improved antithrombotic activity and diminished bleeding side effect of a PEGylated αIIbβ3 antagonist, disintegrin. Toxins (Basel) 2020; 12 (07) 12
    PubMedSearch in Google Scholar
  • 11 Farrell DH, Thiagarajan P, Chung DW, Davie EW. Role of fibrinogen alpha and gamma chain sites in platelet aggregation. Proc Natl Acad Sci U S A 1992; 89 (22) 10729-10732
    CrossrefPubMedSearch in Google Scholar
  • 12 Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008; 359 (09) 938-949
    CrossrefPubMedSearch in Google Scholar
  • 13 Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114 (08) 774-782
    CrossrefPubMedSearch in Google Scholar
  • 14 Jasuja R, Furie B, Furie BC. Endothelium-derived but not platelet-derived protein disulfide isomerase is required for thrombus formation in vivo. Blood 2010; 116 (22) 4665-4674
    CrossrefPubMedSearch in Google Scholar
  • 15 Mieszczak C, Winther K. Does warfarin enhance platelet activity?. Thromb Res 1996; 84 (04) 285-287
    CrossrefPubMedSearch in Google Scholar
  • 16 Connors JM. Testing and monitoring direct oral anticoagulants. Blood 2018; 132 (19) 2009-2015
    CrossrefPubMedSearch in Google Scholar
  • 17 Barbato E, Mehilli J, Sibbing D, Siontis GCM, Collet JP, Thiele H. ESC Scientific Document Group. Questions and answers on antithrombotic therapy and revascularization strategies in non-ST-elevation acute coronary syndrome (NSTE-ACS): a companion document of the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021; 42 (14) 1368-1378
    CrossrefPubMedSearch in Google Scholar
  • 18 Bohula EA, Berg DD, Lopes MS. et al; COVID-PACT Investigators. Anticoagulation and antiplatelet therapy for prevention of venous and arterial thrombotic events in critically ill patients with COVID-19: COVID-PACT. Circulation 2022; 146 (18) 1344-1356
    CrossrefPubMedSearch in Google Scholar
  • 19 Yarrington CD, Valente AM, Economy KE. Cardiovascular management in pregnancy: antithrombotic agents and antiplatelet agents. Circulation 2015; 132 (14) 1354-1364
    CrossrefPubMedSearch in Google Scholar
  • 20 Castellucci LA, Cameron C, Le Gal G. et al. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ 2013; 347: f5133
    CrossrefPubMedSearch in Google Scholar
  • 21 Collet JP, Thiele H, Barbato E. et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) (vol 42, pg 1289, 2021). Eur Heart J 2021; 42: 2298-2298
    CrossrefPubMedSearch in Google Scholar
  • 22 Izadpanah M, Khalili H, Mohammadi M. Comparing safety of heparin as continuous intravenous infusion and multiple subcutaneous injections. J Comp Eff Res 2016; 5 (01) 31-38
    CrossrefPubMedSearch in Google Scholar
  • 23 Amirtabar A, Vazquez SR, Saunders J, Witt DM. Antiplatelet therapy indication in patients also prescribed direct oral anticoagulants. J Thromb Thrombolysis 2023; 55 (01) 185-188
    CrossrefPubMedSearch in Google Scholar
  • 24 Burzynski LC, Humphry M, Pyrillou K. et al. The coagulation and immune systems are directly linked through the activation of interleukin-1α by Thrombin. Immunity 2019; 50 (04) 1033-1042 -.e6
    CrossrefPubMedSearch in Google Scholar
  • 25 Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 2013; 13 (01) 34-45
    CrossrefPubMedSearch in Google Scholar
  • 26 Jackson SP. Arterial thrombosis–insidious, unpredictable and deadly. Nat Med 2011; 17 (11) 1423-1436
    CrossrefPubMedSearch in Google Scholar
  • 27 Hu L, Fan Z, Du H. et al. BF061, a novel antiplatelet and antithrombotic agent targeting P2Y12 receptor and phosphodiesterase. Thromb Haemost 2011; 106 (06) 1203-1214
    Thieme ConnectPubMedSearch in Google Scholar
  • 28 Zhang S, Zhang S, Hu L. et al. Nucleotide-binding oligomerization domain 2 receptor is expressed in platelets and enhances platelet activation and thrombosis. Circulation 2015; 131 (13) 1160-1170
    CrossrefPubMedSearch in Google Scholar
  • 29 Su S, Yu Y, Mo W. et al. A development of LC-MS method combining ultrafiltration and lyophilization for determination of r-RGD-Hirudin in human serum. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 870 (01) 27-31
    CrossrefPubMedSearch in Google Scholar
  • 30 Zhao B, Zhang Y, Huang Y. et al. A novel hirudin derivative inhibiting thrombin without bleeding for subcutaneous injection. Thromb Haemost 2017; 117 (01) 44-56
    Thieme ConnectPubMedSearch in Google Scholar
  • 31 Li YR, Huang YN, Zhao B. et al. RGD-hirudin-based low molecular weight peptide prevents blood coagulation via subcutaneous injection. Acta Pharmacol Sin 2020; 41 (06) 753-762
    CrossrefPubMedSearch in Google Scholar
  • 32 Lenain N, Freund M, Léon C, Cazenave JP, Gachet C. Inhibition of localized thrombosis in P2Y1-deficient mice and rodents treated with MRS2179, a P2Y1 receptor antagonist. J Thromb Haemost 2003; 1 (06) 1144-1149
    CrossrefPubMedSearch in Google Scholar
  • 33 Barrett NE, Holbrook L, Jones S. et al. Future innovations in anti-platelet therapies. Br J Pharmacol 2008; 154 (05) 918-939
    CrossrefPubMedSearch in Google Scholar
  • 34 McFadyen JD, Peter K. Novel antithrombotic drugs on the horizon: the ultimate promise to prevent clotting while avoiding bleeding. Circ Res 2017; 121 (10) 1133-1135
    CrossrefPubMedSearch in Google Scholar
  • 35 Vandendries ER, Hamilton JR, Coughlin SR, Furie B, Furie BC. Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis. Proc Natl Acad Sci U S A 2007; 104 (01) 288-292
    CrossrefPubMedSearch in Google Scholar
  • 36 Jasuja R, Passam FH, Kennedy DR. et al. Protein disulfide isomerase inhibitors constitute a new class of antithrombotic agents. J Clin Invest 2012; 122 (06) 2104-2113
    CrossrefPubMedSearch in Google Scholar
  • 37 Sun Y, Wang B, Pei J. et al. Molecular dynamic and pharmacological studies on protein-engineered hirudin variants of Hirudinaria manillensis and Hirudo medicinalis. Br J Pharmacol 2022; 179 (14) 3740-3753
    CrossrefPubMedSearch in Google Scholar
  • 38 Slack RJ, Macdonald SJF, Roper JA, Jenkins RG, Hatley RJD. Emerging therapeutic opportunities for integrin inhibitors. Nat Rev Drug Discov 2022; 21 (01) 60-78
    CrossrefPubMedSearch in Google Scholar
  • 39 Chen S, Lv K, Sharda A. et al. Anti-thrombotic effects mediated by dihydromyricetin involve both platelet inhibition and endothelial protection. Pharmacol Res 2021; 167: 105540
    CrossrefPubMedSearch in Google Scholar
  • 40 Anselmo AC, Gokarn Y, Mitragotri S. Non-invasive delivery strategies for biologics. Nat Rev Drug Discov 2019; 18 (01) 19-40
    CrossrefPubMedSearch in Google Scholar
  • 41 Piran S, Schulman S. Treatment of bleeding complications in patients on anticoagulant therapy. Blood 2019; 133 (05) 425-435
    CrossrefPubMedSearch in Google Scholar
  • 42 Burr N, Lummis K, Sood R, Kane JS, Corp A, Subramanian V. Risk of gastrointestinal bleeding with direct oral anticoagulants: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 2017; 2 (02) 85-93
    CrossrefPubMedSearch in Google Scholar
  • 43 Wu M, Xia T, Li Y. et al. Design and fabrication of r-hirudin loaded dissolving microneedle patch for minimally invasive and long-term treatment of thromboembolic disease. Asian J Pharm Sci 2022; 17 (02) 284-297
    CrossrefPubMedSearch in Google Scholar
  • 44 Li QQ, Yang YX, Qv JW. et al. Investigation of interactions between thrombin and ten phenolic compounds by affinity capillary electrophoresis and molecular docking. J Anal Methods Chem 2018; 2018: 4707609
    PubMedSearch in Google Scholar